NHI.no
Annonse
Informasjon

Prostataoperasjon

Prostataoperasjon foretas ved godartet forstørret prostata som skaper store vannlatingsproblemer, og ved prostatakreft.

Prostataoperasjon kan foregå på flere forskjellige måter. Enten gjennom urinrøret, ved åpen operasjon, ved kikkhullskirurgi eller ved ulike metoder som brenner vekk prostatavev.

Sist oppdatert:

23. juli 2020

Dette dokumentet er basert på det profesjonelle dokumentet Prostatakreft . Referanselisten for dette dokumentet vises nedenfor

  1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Helsedirektoratet. Sist faglig oppdatert 27.01.2023. Siden besøkt 05.10.2023. www.helsedirektoratet.no
  2. Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012 Jan;60(1):59-74. doi: 10.1111/j.1365-2559.2011.04039.x. PMID: 22212078 PubMed
  3. Kreftlex. Utredning ved prostatakreft. Institutt for kreftgenetikk og informatikk, 2023. kreftlex.no
  4. Kreftregisteret. Kreft i Norge. Siden sist oppdatert 10.05.2023. www.kreftregisteret.no
  5. Kreftregisteret. Årsrapport for prostatakreft 2022. Publisert 10. mai 2022. www.kreftregisteret.no
  6. Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci. 2020 Jul 16;21(14):5036. doi: 10.3390/ijms21145036. PMID: 32708810 PubMed
  7. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012 Apr;30(2):143-8. doi: 10.1007/s00345-011-0801-1. Epub 2011 Nov 25. PMID: 22116601 PubMed
  8. European Association of Urology (EAU). Prostate Cancer. 2023 [cited 2023 7th October]. uroweb.org
  9. Helsedirektoratet. Diagnoseveiledere. Prostatakreft. Sist faglig oppdatert 02. august 2018. Siden lest 07. oktober 2023. www.helsedirektoratet.no
  10. Carlsson S, Adolfsson J, Bratt O, et al. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol. 2009;43(5):350-6. doi: 10.3109/00365590902916930. PMID: 19921978 PubMed
  11. Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2. PMID: 30288918 PubMed
  12. Frånlund M, Månsson M, Godtman RA, et al. Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. J Urol. 2022 Aug;208(2):292-300. doi: 10.1097/JU.0000000000002696. Epub 2022 Apr 15. PMID: 35422134 PubMed
  13. Würnschimmel C, Chandrasekar T, Hahn L, Esen T, Shariat SF, Tilki D. MRI as a screening tool for prostate cancer: current evidence and future challenges. World J Urol. 2023 Apr;41(4):921-928. doi: 10.1007/s00345-022-03947-y. Epub 2022 Feb 28. PMID: 35226140 PubMed
  14. Legeforeningen. Gjør kloke valg. Norsk forening for allmennmedisin. Unngå å måle PSA uten først å vurdere risiko og indikasjon ved hjelp av anamnese og klinisk undersøkelse. Publisert 4. juli 2018. Siden besøkt 05.10.2023 www.legeforeningen.no
  15. Nasjonal brukerhåndbok i Medisinsk biokjemi. PSA, P. Sist endret 30.11.2021. Siden lest 13.10.2023. metodebok.no
  16. Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51. PubMed
  17. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46. New England Journal of Medicine
  18. Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol. 2002 Nov;168(5):1990-3. doi: 10.1016/S0022-5347(05)64279-6. PMID: 12394692 PubMed
  19. Hagens MJ, Fernandez Salamanca M, Padhani AR, van Leeuwen PJ, van der Poel HG, Schoots IG. Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2022 May 2;40:95-103. doi: 10.1016/j.euros.2022.04.001. PMID: 35540708 PubMed
  20. Distler FA, Radtke JP, Bonekamp D, et al. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction. J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31. PMID: 28373135 PubMed
  21. Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ. 2018 May 3;361:k1202. doi: 10.1136/bmj.k1202. PMID: 29724877 PubMed
  22. Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol. 2017 Aug;35(8):1199-1203. doi: 10.1007/s00345-016-1985-1. Epub 2016 Dec 16. PMID: 27987032 PubMed
  23. Jacewicz M, Günzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2022 Oct;22(10):1465-1471. doi: 10.1016/S1473-3099(22)00373-5. Epub 2022 Jul 12. PMID: 35839791 PubMed
  24. Faria R, Soares MO, Spackman E, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. 2018 Jan;73(1):23-30. doi: 10.1016/j.eururo.2017.08.018. Epub 2017 Sep 19. PMID: 28935163 PubMed
  25. Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):256-263. doi: 10.1038/s41391-021-00417-1. Epub 2021 Jul 6. PMID: 34230616 PubMed
  26. Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, Sone T. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283. Epub 2020 Jul 2. PMID: 32614123 PubMed
  27. Bratt O, Lilja H. Modern prostate cancer diagnostics reduce overdiagnosis - will they open up for population-based screening? Scand J Urol. 2021 Dec;55(6):491-492. doi: 10.1080/21681805.2021.1980608. Epub 2021 Oct 4. PMID: 34605720 PubMed
  28. Raabe NK, Normann M, Lilleby W. Lavdoserate brakyterapi ved lavgradig prostatakreft. Tidsskr Nor Legeforen 2015; 135: 548-52. pmid:25806763 PubMed
  29. Raabe NK, Lilleby W, Tafjord G, Åstrøm L. Høydoserate brakyterapi ved prostatakreft i Norge. Tidsskr Nor Legeforen 2008; 128: 1275-8. PubMed
  30. Lardas M, Liew M, van den Bergh RC, et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 Dec;72(6):869-885. doi: 10.1016/j.eururo.2017.06.035. Epub 2017 Jul 27. PMID: 28757301 PubMed
  31. Europa UOMO. EUPROMS Quality of Life. 2023 [cited 2023 08 October] www.europa-uomo.org
  32. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358-67. PubMed
  33. Wallis CJD, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016; 352: i851. doi:10.1136/bmj.i851 DOI
  34. Bagshaw HP, Arnow KD, Trickey AW et al. Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer. JAMA Netw Open. 2022 Jul 1;5(7):e2223025. PMID: 35900763. PubMed
  35. Jayadevappa R, Chhatre S, Malkowicz B, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2: e196562. pmid:31268539 PubMed
  36. Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2017. PMID: 28841388 PubMed
Annonse
Annonse